Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
D3.260 - Bempedoic acid allergy in a patient with hypercholesterolemia
- D3.262 - Bempedoic acid allergy in a statin-intolerant patient with hypercholesterolemia
D3.252 - Azithromycin and Mycoplasma pneumonia: an unusual Stevens-Johnson syndrome case
D3.256 - Is an Early-Type Hypersensitivity Reaction Possible with Both Peroral and Parenteral Anticoagulant Drugs? A Successful 2-Day Peroral Desensitization Protocol to Rivaroxaban
D3.257 - Two cases of propofol anaphylaxis revealed by provocation test
D3.258 - Probable drug- induced Enterocolitis Syndrome (DIES) caused by Amoxicillin
D3.259 - KOLLIPHOR : An excipient to be futher explored
D3.263 - Rare case of anaphylaxis to lidocaine in skin testing during perioperative anaphylaxis investigation
D3.264 - Pioneering study evaluating the Basophil Activation Test (BAT), PENFAST and skin sensitization to penicillin in patients with gestational syphilis
D3.423 - Cross-Reactivity Among Hymenoptera Venoms: A Case Study on Apis, Vespula, and Polistes Allergens
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download